Skip to main content

KineMed, GSK Partner on Biomarker Discovery Deal

NEW YORK (GenomeWeb News) – KineMed today announced an agreement with GlaxoSmithKline for the use of KineMed's biomarker discovery platform in therapeutic areas of interest for the drug manufacturer.

The deal is aimed at the discovery, optimization, and validation of novel biomarkers for use in clinical trials directed at compounds for muscle wasting, fibrosis, and metabolic diseases. Marc Hellerstein, KineMed's chief of the scientific advisory board, said that reliable biomarkers that measure the therapeutic impact of drugs on the underlying disease processes are the missing links in developing drugs that target such diseases.

"KineMed's technology, which measures the dynamics of cellular biochemical networks, is focused on developing better metrics of the disease pathology of those disorders and therefore generates competitive advantage in developing effective drugs against them," he said in a statement.

Financial and other terms of the multiyear deal were not disclosed.

Based in Emeryville, Calif., KineMed discovers and develops biomarkers. It announced a deal with CHDI Foundation targeting Huntington's disease, and one with Pfizer to develop diabetes treatments, as GenomeWeb Daily News sister publication ProteoMonitor has reported.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.